Joseph Tyndall Acquires Shares in Axogen, Inc.

Joseph Tyndall bought 14,150 shares of Axogen, Inc. on June 19, 2026. The transaction wasn't part of a planned trading program. Shares of Axogen, Inc. (NasdaqCM:AXGN) traded near $44.95 on Wednesday.

Insider Buying and Selling at Axogen, Inc.

On June 19, 2026, several insiders, including Joseph Tyndall, purchased shares of Axogen, Inc. Each bought 14,150 shares. Paul Thomas also purchased 18,867 shares on the same day. These transactions were not executed under Rule 10b5-1 plans.

Other Institutional Activity in Axogen, Inc.

Several institutional investors have shown interest in Axogen, Inc. Recently, First Light Asset Management, LLC reduced its holdings by 1,230,558 shares, ending with 4,002,768 shares worth about $132.6 million. BlackRock, Inc. increased its stake by 151,414 shares, bringing its total to 3,870,851 shares valued at approximately $128.2 million. Morgan Stanley added 536,112 shares, resulting in a 20.7% increase, for a total of 3,122,982 shares valued at $103.5 million. Vanguard Capital Management LLC opened a new position with 2,291,563 shares, valued at $75.9 million.

Axogen, Inc. Stock Up 0.2%

As of Wednesday, shares of Axogen, Inc. traded near $44.95. The company, with a market cap of $2.39 billion, operates in the healthcare sector, specifically in medical devices. Axogen has a forward P/E ratio of 61.7 and a beta of 1.118. The stock’s 52-week range is between $9.35 and $45.83. It has a 50-day moving average of $40.43 and a 200-day moving average of $30.40. The company's current ratio is 7.101, with a quick ratio of 4.994 and a debt-to-equity ratio of 8.432.

Analysts Set New Price Targets

On April 29, 2026, Canaccord Genuity maintained its 'buy' rating for Axogen, Inc. with a price target of $50. Wells Fargo also maintained a 'buy' rating with a $48 price target. Overall, the consensus among nine analysts is a 'buy' recommendation, with a mean price target of $50.78.

About Axogen, Inc.

Axogen, Inc., headquartered in Alachua, Florida, develops and sells technologies for peripheral nerve regeneration and repair. The company offers a range of products, including the Avance Nerve Graft and Axoguard Nerve Protector, used by surgeons in various specialties. Under the leadership of CEO Michael D. Dale, Axogen serves hospitals and surgery centers globally, employing 622 people.

Bottom Line

Joseph Tyndall's recent purchase of Axogen, Inc. shares highlights insider confidence in the company's prospects. Axogen, with a strong position in the medical devices sector, is closely watched by investors and analysts. The stock's performance and upcoming earnings report on August 4, 2026, will be key areas of focus.